Lowest Price Guaranteed From USD 3,999
Earlier, customers from North America demonstrated a preference for service providers within the US to outsource their ADME requirements; however, clients are now more willing to work across borders. Despite growing activity in other upcoming regions, I believe that the major proportion of activity in this field is still restricted to within North America, followed by Asia-Pacific and Europe.
-- Chief Scientific Officer, a US-based small-sized CRO
The global in vitro ADME toxicology testing market is currently around $2.2 billion and is expected to grow at a CAGR of 9.8% till 2030. The early stages of drug discovery research, which include the identification of a relevant biological target and a viable lead compound with therapeutic potential, play a crucial role in the overall success of a drug candidate in both preclinical and clinical studies. It is also important to note that the process of drug discovery is extremely demanding, both in terms of capital and time. In fact, the overall amount spent in R&D initiatives in the pharmaceutical / biotechnology sector has increased from around USD 128 billion in 2008 to USD 165 billion in 2018. Moreover, only a small fraction of early stage therapeutic candidates are able to make it past preclinical evaluation. According to a study conducted on terminated drug development programs, the high rate of failure of drugs in clinical trials was primarily attributed to problems associated with their pharmacokinetic profiles, absorption, distribution, metabolism and excretion (ADME) properties and inherent toxicity. As a result, the industry is currently under tremendous pressure to not only meet the expectations of a growing patient population, but to also identify ways to mitigate the risks associated with discovery programs of novel drug / therapy molecules.
Specifically, ADME studies are considered to be critical in establishing the safety and efficacy of drug candidates. Currently, there are a number of contract research organizations (CROs) that claim to have the necessary capabilities to offer in vitro ADME services. Over time, such service providers have grown to become an indispensable part of the pharmaceutical / biopharmaceutical market. Moreover, advances in combinatorial chemistry and high throughput screening in the last decade have made it possible to carry out early stage ADME screening for a large number of compounds in a more cost and time efficient manner. In less than a decade, the ADME services industry has witnessed noteworthy consolidation, with many of the smaller players being acquired by more established firms in efforts to augment services portfolios and widen geographical reach. Further, given the growing demand for high quality pharmacological interventions, and the cost and time-related benefits of outsourcing in vitro ADME research, the demand for CROs is projected to witness a significantly market growth during the forecast period.
Examples of key service providers engaged in ADME toxicology testing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Albany Molecular Research (AMRI), Charles River Laboratories, Pharmaceutical Product Development (PPD), RTI International, Eurofins Scientific, Evotec, Galapagos, Tecan Group, GVK Biosciences, Pharmaron, Sai Life Sciences, Shanghai Medicilon, Syngene International and WuXi AppTec. This market report includes an easily searchable excel database of all the companies providing ADME toxicology testing services, worldwide.
Several recent developments have taken place in in vitro ADME toxicology testing market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The "In Vitro ADME Toxicology Testing Market, 2019-2030" market report features a comprehensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the in vitro ADME toxicology testing market. The market research report presents an in-depth analysis, highlighting the capabilities of various stakeholders across different global regions.
Amongst other elements, the market research report includes:
The key objective of in vitro ADME toxicology testing market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for in vitro ADME toxicology testing market during the forecast period. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the forecast period 2019-2030. In addition, we have segmented the future opportunity across [A] different global regions (North America, Europe, Asia-Pacific and rest of the world), [B] type of services (absorption, distribution, metabolism and excretion), [C] type of assays (across 5+ categories), [D] type of molecule(s) (biologics and small molecules), [E] type of sponsor company (pharmaceutical / biotechnology companies and academic / research institutes) and [F] therapeutic areas (across 10+ categories). To account for the uncertainties associated with the in vitro ADME toxicology testing market and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the market report were also influenced by discussions conducted with several stakeholders in ADME toxicology testing market. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.